Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

It’s The Way Medical Science Is Done

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
falconer66a Member Profile
 
Followed By 70
Posts 1,355
Boards Moderated 0
Alias Born 01/29/04
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
falconer66a   Thursday, 05/02/19 08:53:44 PM
Re: nidan7500 post# 191404
Post # of 231093 
It’s The Way Medical Science Is Done

I’m not at all surprised with the reluctance, even resistance with which the medical research community disregards virtually all of the Anavex story. It’s something learned as an undergraduate science major. First, just lots of stuff to learn. So be sure to learn the “right stuff,” the material from the “right people.” The entire enterprise is run and controlled by the right people (expert professors) who have all the right information (theirs).

Undergrad science majors learn early on how to play the game. Ask the right kinds of questions. Don’t bring in any sort of external, unaccepted, or questionable information. Stay focused on what is actually known (meaning, what the professor believes). Aberrant, controversial, or hazy information or concepts that are put forth by an undergrad jeopardize his standing with the instructor. Stay focused and confined to what’s known. That demonstrates one to be a real student.

Then, science students have to learn how to conduct valid research. Validity, by and large, is demonstrated by generating statistically significant data. Be sure to demonstrate that derived experimental data have no more than a one in twenty chance (0.05) of being caused by chance, not the tested factors.

In short, the formal training of scientists simply does not in any way promote out of the box, new, or innovative thinking. The whole game is to keep investigations narrowly confined to what is known or understood; merely to more accurately substantiate existing bodies of knowledge. To conduct exciting new research in new areas, with new ideas dramatically lessens the chances of yielding statistically significant data. With out of range P values, the findings, arbitrarily, can not be accepted. Yes, the results might actually be correct; some really new things might have been demonstrated. But, who knows? Dare not take a chance with it.

Those are the constraints of undergrads and grad students doing their own research. But it’s exactly the same for doctoral and post-doctoral research. There is throughout modern science a decided pressure to restrain research to what it known; merely to more thoroughly confirm it. The consideration and testing of innovative, novel, and untested ideas can be career-jeopardizing.

Dozens of MDs and PhDs have read all of the Anavex research papers I have; even understood them better than I could. Privately, they know full well that the data, both murine and human, are valid; that the Anavex sigma-1 receptor agonists will yield profound therapeutic outcomes.

Why, then, no generalized acceptance or recognition of Anavex? Not enough people yet know. It’s not yet shared, mutually understood knowledge. For a PhD to state to her colleagues that Anavex is really on to something would evoke looks of alarm or astonishment. “What do you mean? That can’t be true. No molecule can rejuvenate a dysfunctional neuron. Get real.”

Since Hippocrates in the 4th century BCE medicine has always resisted new understandings. Of all the sciences, medical science has always been the most reluctant to change or accept new knowledge. “Nope, that’s not what my med school professor taught me; can’t be true. Alzheimer’s can’t be treated or prevented; period.”

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist